Oral retinoids are often used to treat pustular psoriasis ... You have serious liver or kidney disease. You have high triglycerides. Systemic biologic psoriasis treatments These are newer drugs ...

A new study published in the journal of BMC Pulmonary Medicine showed that 10% of psoriasis patients would have interstitial ...

Research has found that arachidonic acid can create chemicals that cause inflammation, which may worsen the red, scaly patches seen in psoriasis. Celiac disease is a health condition characterized ...

Joel Thomas works hard at his job as an I-T specialist. He also works hard to stay healthy despite his history of psoriasis. Joel Thomas I have an echocardiogram done every year just to make sure ...

Psoriasis is a skin disease that causes itchy plaques or scaly bumps to develop on the skin. It can affect any area of your body, but these plaques commonly pop up on elbows, knees, and scalp.

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...

There are two major forms of psoriasis: plaque psoriasis, the more common one, and pustular psoriasis, the more severe but ...

Psoriasis is a chronic inflammatory disease affecting 2% of the adult population. Common cutaneous manifestations include well-defined red plaques with a silvery-white scale, typically distributed ...

Skyrizi is important for AbbVie as sales of its Humira (adalimumab) inflammatory disease mega-blockbuster ... a licence for plaque psoriasis, generalised pustular psoriasis, erythrodermic ...

IT’S not often that one sees avant-garde dresses being displayed at a medical conference, but that was certainly the case during the recent 25th World Congress of Dermatology in Singapore.

Secukinumab is under clinical development by Novartis and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Zasocitinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Systemic Lupus Erythematosus.